Kymab Revenue and Competitors
Estimated Revenue & Valuation
- Kymab's estimated annual revenue is currently $11.3M per year.
- Kymab's estimated revenue per employee is $155,000
Employee Data
- Kymab has 73 Employees.
- Kymab grew their employee count by -42% last year.
Kymab's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Technology | Reveal Email/Phone |
2 | Head Project Management Office, Operations & Communication | Reveal Email/Phone |
3 | Head (Director) Bioanalysis | Reveal Email/Phone |
4 | Associate Director | Reveal Email/Phone |
5 | Director | Reveal Email/Phone |
6 | Senior Director, Operations | Reveal Email/Phone |
7 | Associate Director - Informatics | Reveal Email/Phone |
8 | Associate Project Manager | Reveal Email/Phone |
9 | Senior Clinical Project Manager | Reveal Email/Phone |
10 | Project Manager | Reveal Email/Phone |
Kymab Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Kymab?
Kymab is a clinical-stage global biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available. Kymab's platform has been designed to maximise the diversity of human antibodies produced in response to immunisation with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is using the platform for its internal drug discovery programmes and in partnership with pharmaceutical companies. Kymab was founded in 2010 and has raised over US$220m of equity financing. It has an experienced management team with a successful track record in drug discovery and development and a broad pipeline of therapeutic antibody programmes in immune-oncology, auto-immunity, haematology, infectious disease and other areas.
keywords:Biotechnology,Healthcare,Pharmaceuticals
N/A
Total Funding
73
Number of Employees
$11.3M
Revenue (est)
-42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kymab News
Sanofi to acquire Kymab 11-01-2021 Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an up ...
Sanofi to acquire Kymab 11-01-2021 Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an up ...
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics, is pleased to announce that the Supreme ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $11.4M | 73 | 18% | N/A |
#2 | $11.3M | 73 | -4% | N/A |
#3 | $16M | 73 | 6% | N/A |
#4 | $1.7M | 73 | 46% | N/A |
#5 | $11.8M | 73 | 18% | N/A |